Pegcantratinib

Pegcantratinib (CT327) is a potent and selective TRKA antagonist with activity against TRKB and TRKC. Pegcantratinib can be used for research of CYLD cutaneous syndrome (CCS) and inflammatory dermatoses, such as psoriasis and concomitant pruritus[1].

Product Specifications

CAS Number

[1233363-33-1]

Product Name Alternative

CT327; SNA-120

UNSPSC

12352100

Target

Trk Receptor

Related Pathways

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C(N(CCOCCCOCC)C(O1)=O)[C@@]21[C@](C)(O3)N(C4=CC=CC=C45)C6=C5C7=C(C(NC7)=O)C8=C6N([C@H]3C2)C9=CC=CC=C98.[n]

Molecular Formula

(C2H4O) nC30H24N4O6

References & Citations

[1]Danilenko M, et al. Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial. JAMA Dermatol. 2018 Aug 1;154 (8) :913-921.